Allan MD - Prime Medicine, Chief Officer
| PRME Etf | USD 2.01 0.01 0.50% |
| Age | 50 |
| Address | 21 Erie Street, Cambridge, MA, United States, 02139 |
| Phone | 617 564 0013 |
| Web | https://primemedicine.com |
Prime Medicine, Management Efficiency
The company has return on total asset (ROA) of (0.5151) % which means that it has lost $0.5151 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3688) %, meaning that it created substantial loss on money invested by shareholders. Prime Medicine,'s management efficiency ratios could be used to measure how well Prime Medicine, manages its routine affairs as well as how well it operates its assets and liabilities.Similar Fund Executives
| Showing other executives | One Year Return | ||
| Terry MD | Sana Biotechnology | 57 | |
| Sandy Balkin | Royalty Pharma Plc | N/A | |
| Anna MBA | Ginkgo Bioworks Holdings | 35 | |
| Kaitlin Duffy | Verve Therapeutics | N/A | |
| Troy Lister | Verve Therapeutics | N/A | |
| Linda Burkly | Editas Medicine | 67 | |
| Caren Deardorf | Editas Medicine | 60 | |
| Ariel Hurley | Blueprint Medicines Corp | 51 | |
| Morgan Conn | Century Therapeutics | 56 | |
| Joshua Dunn | Ginkgo Bioworks Holdings | N/A | |
| Patrick Boyle | Ginkgo Bioworks Holdings | N/A | |
| Ryan Fischesser | Caribou Biosciences | N/A | |
| Karen Tepichin | Ginkgo Bioworks Holdings | N/A | |
| Chad Cowan | Century Therapeutics | N/A | |
| Samarth Kulkarni | Crispr Therapeutics AG | 47 | |
| Sara Klymkowsky | Royalty Pharma Plc | N/A | |
| Anna Wagner | Ginkgo Bioworks Holdings | N/A | |
| James Reddoch | Royalty Pharma Plc | 54 | |
| Deborah Palestrant | Relay Therapeutics | N/A | |
| Paul MD | Sana Biotechnology | N/A | |
| Michael CPA | Blueprint Medicines Corp | 53 | |
Management Performance
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.52 |
Prime Medicine, Common Money Managers
| David Liu, CoFounder Board | ||
| Meredith Goldwasser, Senior Operations | ||
| Andrew MD, CoFounder Platform | ||
| Richard Brudnick, Chief Officer | ||
| Keith MD, CEO and President | ||
| Ann Lee, Chief Officer | ||
| Karen JD, Senior Affairs | ||
| Allan MD, Chief Officer | ||
| Niamh Alix, Chief Officer | ||
| Keith Gottesdiener, CEO and Presidentident |
Prime Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Prime Medicine, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (20.26) % | ||||
| Current Valuation | 81.2 M | ||||
| Shares Outstanding | 131.16 M | ||||
| Shares Owned By Insiders | 23.90 % | ||||
| Shares Owned By Institutions | 59.05 % | ||||
| Number Of Shares Shorted | 18.06 M | ||||
| Price To Earning | 14.40 X | ||||
| Price To Book | 1.51 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.